VYNE Therapeutics Inc.
VYNE
$0.36
-$0.02-4.02%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -5.76M | -8.61M | -12.02M | -12.16M | -9.41M |
| Total Depreciation and Amortization | 6.00K | 6.00K | 4.00K | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 315.00K | 439.00K | 154.00K | 229.00K | 269.00K |
| Change in Net Operating Assets | -5.37M | -3.30M | 2.87M | 3.42M | 655.00K |
| Cash from Operations | -10.80M | -11.46M | -9.00M | -8.51M | -8.48M |
| Capital Expenditure | -- | -- | -117.00K | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 4.68M | 19.83M | 12.86M | -4.82M | 19.02M |
| Cash from Investing | 4.68M | 19.83M | 12.74M | -4.82M | 19.02M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -34.00K | -87.00K | -132.00K | -2.00K | -2.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -34.00K | -87.00K | -132.00K | -2.00K | -2.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -6.16M | 8.28M | 3.61M | -13.34M | 10.54M |